BioCryst to Acquire Astria for $920M, Expanding HAE Portfolio

North Carolina & Boston, October 14, 2025 (Business Wire) -- BioCryst Pharmaceuticals will acquire Astria Therapeutics for an implied equity value of $920 million and enterprise value of $700 million. The deal adds Astria’s late-stage injectable HAE therapy, navenibart, to BioCryst’s portfolio, supporting a projected double-digit growth trajectory. BioCryst expects to remain profitable and cash flow positive post-transaction, with the deal expected to close in Q1 2026.

Read full article here.